Boehringer Ingelheim entered a collaboration agreement with Re-Vana Therapeutics centered on Re-Vana’s ocular extended-release drug delivery platform aimed at reducing injection frequency for ophthalmic patients. The deal includes up to $1 billion in upfront and milestone payments linked to initial targets. Boehringer plans to combine this platform with its phase 2-stage eye disease assets, including therapies for diabetic retinopathy and geographic atrophy. The partnership represents Boehringer’s significant expansion into eye health, aiming to improve patient compliance and therapeutic outcomes in this field.